Navigation Links
ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
Date:6/24/2011

thorization Applications (MAAs) for medicines for human use. Their positive opinion forms the scientific basis for the European Commission to issue a binding decision for an MAA or a PUMA, a centralized marketing authorization which is valid throughout all the Member States of the European Union (EU) as well as in the European Economic Area (EEA), namely Norway, Iceland and Liechtenstein. The anticipated timeframe for the European Commission decision is by the fourth quarter of 2011.  A summary of the CHMP opinion will be available here: http://tinyurl.com/2am4ubc.  Please select "B" to access the Buccolam summary opinion.  

"This positive CHMP opinion - the first for a product seeking centralized authorization through a PUMA - is a great step towards the European marketing authorization for Buccolam, a product that addresses significant unmet need for families and caregivers – namely the quick and effective termination of prolonged, acute convulsive seizures in children and adolescents," commented Thierry Darcis, M.D., ViroPharma's vice president, general manager, Europe.  "We will work closely with physicians across Europe on improving the seizure treatment paradigm, and bringing this much-needed emergency medication to market as soon as possible this year."

A Pediatric Use Marketing Authorization (PUMA) is a new type of centralized marketing authorization procedure for medicines that are developed specifically for children and may already be authorized for other indications or routes of administration in adults but are not patented. These medicines benefit from 10 years of market protection as an incentive.  In August 2010, the EMA's Pediatric Committee (PDCO) confirmed that the required Pediatric Investigation Plan (PIP) for Buccolam had been fully completed.  

About Buccolam® (Midazolam, Oromucosal Solution)

Buccolam is oral midazolam prov
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
2. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
3. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
4. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
5. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
6. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
7. ViroPharma to Participate In Three May Healthcare Investor Conferences
8. ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011
9. ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
10. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
11. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... 28, 2015 Research ... addition of the "Investigation Report on China,s ... Developed by Pharmacia & Upjohn in ... which effectively reduces intraocular pressure. As the first ... the trade name of Xalatan) entered ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... 2012  Particle Sciences, a leading drug delivery CRO, ... DOSE™ program.  The DOSE™ program uses a combination ... efficiently arrive at the optimal drug product for ... Sciences implemented software solutions for calculating and predicting ...
... Jan. 3, 2012  Accera, Inc., a privately-held, commercial-stage, healthcare ... therapeutics to treat central nervous system disorders, announced today ... of Chief Executive Officer and as a member of ... Ph.D., has also been appointed as a member of ...
Cached Medicine Technology:Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities 2Accera, Inc. Elects Industry Veteran Holger Kunze as CEO and as a Member of the Company's Board of Directors 2Accera, Inc. Elects Industry Veteran Holger Kunze as CEO and as a Member of the Company's Board of Directors 3
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College joined nine ... experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models ... the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United ... to celebrate children helping children, a thank you to the many creative and ... contributed to the United Methodist initiative to end malaria deaths. , The Columbus ...
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of furthering ... the second year to the Adams County Fairgrounds in Mendon, IL on May 30th, ... money to support music education in the underfunded school districts of Mendon and its ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... As ... from Merz, received FDA clearance for results that last for two years, the ... exciting news for patients who are looking for a long-lasting, effective solution for their ...
(Date:8/28/2015)... ... 2015 , ... Loved ones of a person suffering from ... dependency, may be able to find some hope in the latest video uploads ... addiction located in Western Michigan. Focusing on several different aspects of the powerful ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... The sickle cell trait could be a causealbeit rareof ... during football training, according to a scientific poster ... Cardiology (ACC) Scientific Sessions, April 1-3, in New Orleans. ... 8 percent of African-Americans in the U.S., has been ...
... Fla. A study published in Cancer Discovery, the ... debuting here at the AACR 102nd Annual Meeting 2011, ... in the tumor microenvironment may help researchers better target ... University of California, San Francisco, demonstrated that the level ...
... of a study presented at the AACR 102nd Annual Meeting ... that improving quality of life affects stress-related biological markers and ... that telomeres shorten and deteriorate with aging, but they are ... trying to understand the interconnections between the mind and the ...
... -- Researchers who sequenced the entire genomes of tumors ... mutations, most of which were unique to individual patients. ... predict breast cancer patient outcomes and to find new ... Louis and the Siteman Cancer Center. After sequencing ...
... Highly exciting new data presented today at the ... superior virological response in HCV patients of genotypes ... Pegylated Interferon-alpha (PegIFN-alpha-2a), the current standard of care ... so important because they show PegIFN-lambda could provide ...
... two compounds that inhibit two of the most frequently ... Phase I trial, according to data presented at the ... The research, presented by Johanna Bendell, M.D., ... GDC-0941, which inhibits PI3K. Bendell, director of Gastrointestinal ...
Cached Medicine News:Health News:Young black athletes with sickle cell trait might be susceptible to sudden death 2Health News:Immune system may guide chemotherapy for breast cancer 2Health News:Chronic stress of cancer causes accelerated telomere shortening 2Health News:Most Breast Tumors Have Unique Genetic 'Fingerprint,' Study Finds 2Health News:PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a 2Health News:Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity 2
... Tecans MiniPrep series of robotic workstations ... The MiniPrep is the ideal automation ... automation of routine laboratory procedures, improving throughput, ... based Gemini for MiniPrep software allows you ...
... QFill2 is the ideal system for fast, accurate ... pressure driven, pinch valve controlled dispensing mechanism, ensures ... all of the components that come into contact ... clean, and autoclave. The unique compact design saves ...
... Automatic dispenser for low volumes. Dispenses ... 1536 -well format. Fast throughput of less ... productivity. The dispenser features an intuitive user ... be used to dispense liquids and suspensions, ...
... low volumes. Dispenses volumes down to 0.5ul ... throughput of less than 30 seconds per ... an intuitive user interface that provides one-button ... liquids and suspensions, beads, or cells, with ...
Medicine Products: